Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease

Masaaki Waragai, Madoka Yoshida, Mutsumi Mizoi, Ryotaro Saiki, Keiko Kashiwagi, Kiyoshi Takagi, Hiroyuki Arai, Jun Tashiro, Makoto Hashimoto, Naomichi Iwai, Kenichi Uemura, Kazuei Igarashi

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)


The objective of this study was to determine whether plasma levels of acrolein, a compound that causes cell damage, and amyloid-β (Aβ) are useful biochemical markers for Alzheimer's disease (AD). The study included 221 elderly subjects divided into 101 non-demented [33 healthy control and 68 non-demented subjects with white matter hyperintensity (nd-WMH)], 50 mild cognitive impairment (MCI), and 70 AD. Increases in both protein-conjugated acrolein (PC-Acro) and Aβ40/42 ratio were observed in MCI and AD patients compared with values in control subjects. When the combined measurements of PC-Acro and Aβ40/42 ratio were evaluated using the median value of the relative risk value for dementia, they were in the order AD (0.98) ≥ MCI (0.97) > nd-WMH (0.83) > control (0.35). The results indicate that measurements of PC-Acro and Aβ40/42 ratio not only detect MCI and AD patients but also nd-WMH subjects. Furthermore, both PC-Acro and Aβ40/42 ratio in plasma for 120 MCI and AD patients were significantly higher than those for 101 control and nd-WMH subjects, indicating that both values become useful biochemical markers for MCI and AD subjects.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalJournal of Alzheimer's Disease
Issue number1
Publication statusPublished - 2012


  • Alzheimer's disease
  • amyloid-β
  • magnetic resonance imaging
  • plasma biomarker
  • protein-conjugated acrolein
  • white matter hyperintensity

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health


Dive into the research topics of 'Increased protein-conjugated acrolein and amyloid-β<sub>40/42</sub> ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this